Results for tag: "Ozagrel"

Ozagrel is a hematological drug used to treat thrombocytopenia, a condition characterized by a low platelet count. It is a synthetic form of the naturally occurring compound adenosine, which is known to have anti-platelet effects. Ozagrel is administered intravenously and works by inhibiting the production of thromboxane A2, a compound that is involved in platelet aggregation. This reduces the risk of thrombosis, a potentially life-threatening condition. Ozagrel is also used to treat other hematological conditions such as aplastic anemia and myelodysplastic syndrome. The Ozagrel market is highly competitive, with a number of companies offering their own versions of the drug. These include Daiichi Sankyo, Takeda Pharmaceuticals, and Astellas Pharma. Other companies such as Novartis, Pfizer, and Sanofi are also involved in the development and marketing of Ozagrel. The market is expected to continue to grow in the coming years, as more patients are diagnosed with thrombocytopenia and other hematological conditions. Show Less Read more